The Effect of Taurolidine-Citrate-Heparin Combination on the Inflammatory Response and Hemodialysis Adequacy in Hemodialysis Patients

Abstract

Abstract Background Catheter-related bloodstream infections (CRBSIs) are a significant cause of morbidity and mortality in critically ill patients, contributing to prolonged hospital stays and increased costs. Whether taurolidine lock solutions (TLS) are beneficial for the prevention of CRBSIs remains controversial. Aim and objectives to assess the effect of Taurolock-hep500TM as a lock solution on the incidence of Catheter Related Blood Stream Infections (CRBSI), performance of hemodialysis permanent catheters, and haemodialysis adequacy. Subjects and Methods This study was Randomized Controlled Trial, was carried out on 60 patients at Al-Zaitoun Specialized Hospital -Ministry of Health & Al-Demerdash Hospital – Ain Shams University divided into 2 groups: Taurolidine Group (Group 1): included 30 Patients received Taurolock-hep500TM, (Taurolidine, 4% citrate and 500 IU/ml heparin are combined in this solution), Heparin Group(Group 2)): included 30 Patients will receive unfractionated heparin (heparin sodium 5000i.u/ml) as a permanent catheter lock solution. Patients were followed up for 1 month for monitoring hemodialysis adequacy and incidence of CRBSI. Result CRP was significantly increased in heparin group more than Taurolidine Group. One case with CRBSIs was in Taurolidine Group, whereas five cases in heparin group. Conclusion The use of Taurolidine–citrate–heparin lock solution may be associated with better hemodialysis adequacy, lower incidence of Catheter Related Blood Stream Infections (CRBSI) and lower inflammatory markers in comparison to the use of Heparin.